FinBoss.io
CSEN
  • Home
  • Crypto prices
  • Bitcoin on-chain
  • US macro
  • US stocks
  • Guides
  • How we make money
FinBoss.io
Home
Crypto prices
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Guides
How we make money
CSEN
Home
Stocks
Pfizer
Pfizer

Pfizer

PFEHealth care

Stock · Data from SEC EDGAR 13F · Held by 15 of 87 tracked investors

$30.03
▼ 1.28%
Famous investorshold 15buying 1selling 0
Price (USD)
$30.03
Market cap
$171B
P/E ratio
39.5
Tracked investors holding
15 of 87
Next earnings
3 Nov 2026

Pfizer at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
51out of 100
  • Valuation33
  • Growth21
  • Profitability70
  • Quality57
  • Debt60
  • Stability64
In its favour
  • Nothing notable from the statements.

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 20264 Aug 20260.770.68+13.2%
Mar 20265 May 20260.750.71+5.6%
Dec 20253 Feb 20260.660.57+15.8%
Sep 20254 Nov 20250.870.66+31.8%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

7D
+1.52%
1M
+5.70%
3M
+22.37%
YTD
+19.26%
1Y
+21.28%
3Y
-0.27%
5Y
-31.34%
Forward P/E
10.4
Dividend yield
5.65%
52-week low
$23.62
52-week high
$30.44

Chart PFE

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

15
PW
Prem Watsa
Fairfax Financial Holdings
0.95%$25,116,234▲ +5.3%
KF
Ken Fisher
Fisher Investments
0.78%$2,626,340,379▲ +3.9%
RP
Richard Pzena
Pzena Investment Management
0.42%$143,490,842▲ +0.6%
BB
Bruce Berkowitz
Fairholme Capital Management
0.37%$5,562,480New position
Čn
Česká národní banka
Česká národní banka
0.25%$46,705,892▲ +0.9%
Šn
Švýcarská národní banka
Swiss National Bank
0.2%$386,334,993▼ -3.8%
CA
Cliff Asness
AQR Capital Management
0.16%$445,018,217▲ +56.2%
Ns
Norský státní fond
Norges Bank
0.15%$1,481,054,511New position
MG
Mario Gabelli
GAMCO Investors
0.12%$13,756,567▼ -3.1%
GI
Generali Investments CEE
Generali Investments CEE
0.12%$2,592,164unchanged
JG
Joel Greenblatt
Gotham Asset Management
0.05%$22,062,216▼ -12.9%
RD
Ray Dalio
Bridgewater Associates
0.02%$4,336,615New position
KG
Ken Griffin
Citadel Advisors
0.02%$149,083,759▼ -15.9%
PT
Paul Tudor Jones
Tudor Investment Corp
0.02%$16,783,760New position
JY
Jeff Yass
Susquehanna International Group
0.01%$157,657,684▲ +452%

Frequently asked questions

How much is Pfizer (PFE) stock?

Pfizer shares trade at $30.03, -1.28% over the last trading day. The price is delayed.

What is the market cap of Pfizer?

The market cap of Pfizer is about $171B and its price-to-earnings ratio (P/E) is 39.5.

Does Pfizer pay a dividend?

The dividend yield of Pfizer is 5.65% a year. The yield can change with the company's decisions.

How has Pfizer stock performed over the last year?

The Pfizer share price changed by +21.28% over 12 months and by -31.34% over 5 years.

Which big investors hold Pfizer?

According to the latest 13F filings, 15 of 87 tracked investors hold Pfizer, for example Prem Watsa, Ken Fisher, Richard Pzena.

When will Pfizer report its next results?

The next earnings report of Pfizer is expected on 3 Nov 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms (Czech)Privacy (Czech)Cookies (Czech)

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

What to watch
  • !Revenue fell 14.8% a year over 3 years.
  • !It pays out more in dividends than it earns.
  • !The stock is expensive: you pay 39.5 USD for 1 USD of annual earnings.
  • !In some year revenue fell sharply.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Fairly expensive

For 1 USD of annual earnings you pay 39.5 USD. Based on next year's estimates 10.4 USD.

P/E
39.5×
P/S
2.7×
EV/EBITDA
8.8×

Is the company growing?

Shrinking
22
23
24
25

Revenue over 3 years grew -14.8% a year. Last year 2.6%.

Does it make money?

Weak
  • Cost of sales 26
  • Research 16.7
  • Operations and selling 29.8
  • Taxes and other 15.4
  • Net profit 12.4

Out of 100 USD of revenue, 12.4 USD is left as net profit.

Is it financially healthy?

Mostly
Cash
11.7B USD
Debt
63.5B USD
Free CF
12.5B USD

It could repay its net debt from free cash flow in 4.1 years.

Does it pay a dividend?

Risky
Yield
5.65%
Of earnings
226%

Over a year you receive roughly 5.65% of the price per share. The payout is more demanding for the company. It has raised the dividend for 9 years in a row.

What do analysts expect?

Buy
Average target
29.26 USD
Vs price
−3%

26 analysts. Their opinion is not a recommendation by FinBoss.io.

Which big investors hold it?

15 of 87

Among the tracked investors, Prem Watsa, Ken Fisher, Richard Pzena and others hold the stock according to 13F filings.

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

Dividend per share by year (USD)

* the year has not ended yet. Source: Yahoo Finance.

Ratios

P/E
39.5×
Forward P/E
10.4×
P/B
2.0×
P/S
2.7×
PEG
13.94
EV/EBITDA
8.8×
Gross margin
74.7%
Operating margin
27.9%
Net margin
6.8%
ROE
5.0%
ROA
5.8%
Debt / equity
0.7×
Current ratio
1.3×
Revenue growth
2.6%
Earnings growth
–
Beta
0.28
Dividend
5.65%
Payout ratio
226%